Dynamic Plasma Biomarkers Reveal Multifaceted Effects of Lecanemab in Early Alzheimer’s Disease
This longitudinal study investigates plasma biomarker dynamics in Alzheimer's patients treated with lecanemab, revealing distinct biomarker trajectories that reflect amyloid clearance, tau modulation, and immune responses, offering insights into treatment monitoring and prognostication.